Evaluation of the virus-elimination efficacy of nanofiltration (Viresolve NFP) for the Parvovirus B19 and hepatitis A virus

Korean Journal of Laboratory Medicine

Volumn 30, Issue 1, 2010, Pages 45-50

  Oh, Deok Ja ^a   La Lee, Yoo ^a   Kang, Jae Won ^a   Kwon, So Yong ^a   Cho, Nam Sun ^b   Kim, In Seop ^c  

^a Korean Red Cross   (South Korea)

^b Korean Red Cross   (South Korea)

^c Hannam University   (South Korea)

Author keywords

Hepatitis A virus; Human parvovirus B19; Nanofiltration; Plasma derivatives

Indexed keywords

ANTITHROMBIN III; VIRUS DNA; VIRUS RNA;

ARTICLE; EVALUATION; FILTRATION; GENETICS; HEPATITIS A VIRUS; HUMAN; HUMAN PARVOVIRUS B19; ISOLATION AND PURIFICATION; METHODOLOGY; NANOTECHNOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTITHROMBIN III; DNA, VIRAL; FILTRATION; HEPATITIS A VIRUS; HUMANS; NANOTECHNOLOGY; PARVOVIRUS B19, HUMAN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL;

EID: 77954848286     PISSN: 15986535     EISSN: None     Source Type: Journal    
DOI: 10.3343/kjlm.2010.30.1.45     Document Type: Article

References (18)

1. Mosley JW and Rakela J. Founding viruses and transfusion medicine. Transfusion 1999;39:1041-4.
2. World Health Organization. Recommendations for production, control and regulation of human plasma for fractionation. In: WHO Technical Report Series 941. WHO expert committee on biological standardization. Genava: WHO 2007.
3. Horowitz B. Blood protein derivative viral safety: observations and analysis. Yale J Biol Med 1990;63:361-9.
4. Blümel J, Schmidt I, Effenberger W, Seitz H, Willkommen H, Brackmann HH, et al. Parvovirus B19 transmission by heat-treated clotting factor concentrates. Transfusion 2002;42:1473-81.
5. Wu CG, Mason B, Jong J, Erdman D, McKernan L, Oakley M, et al. Parvovirus B19 transmission by a high-purity factor VIII concentrate. Transfusion 2005;45:1003-10.
6. Chudy M, Budek I, Keller-Stanislawski B, McCaustland KA, Neidhold S, Robertson BH, et al. A new cluster of hepatitis A infection in hemophiliacs traced to a contaminated plasma pool. J Med Virol 1999;57:91-9.
7. Committee for Proprietary Medicinal Products. Note for guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses. http://www.emea.europa.eu/pdfs/human/bwp/026895en.pdf (Update on Feb 1996)
8. Webert KE, Cserti CM, Hannon J, Lin Y, Pavenski K, Pendergrast JM, et al. Proceedings of a consensus conference: pathogen inactivation-making decisions about new technologies. Transfus Med Rev 2008;22:1-34.
9. Yokoyama T, Murai K, Murozuka T, Wakisaka A, Tanifuji M, Fujii N, et al. Removal of small non-enveloped viruses by nanofiltration. Vox Sang 2004;86:225-9.
10. Kleinman SH, Glynn SA, Lee TH, Tobler L, Montalvo L, Todd D, et al. Prevalence and quantitation of parvovirus B19 DNA levels in blood donors with a sensitive polymerase chain reaction screening assay. Transfusion 2007;47:1756-64.
11. Parsyan A and Candotti D. Human erythrovirus B19 and blood transfusion-an update. Transfus Med 2007;17:263-78.
12. Soucie JM, Robertson BH, Bell BP, McCaustland KA, Evatt BL. Hepatitis A virus infections associated with clotting factor concentrate in the United States. Transfusion 1998;38:573-9.
13. Lawlor E, Graham S, Davidson E, Yap PL, Cunningham C, Daly H, et al. Hepatitis A transmission by factor IX concentrates. Vox Sang 1996;71:126-8.
14. U.S. FDA. Viral clearance processes for plasma derivatives. Guide to inspections of viral clearance process for plasma derivatives. http://www.fda.gov/ICECI/Inspections/InspectionGuides/ucm0748 66.htm. (Update on Nov 2009)
15. Committee for Proprietary Medicinal Products. Note for guidance on plasma-derived medical products. http://www.emea.europa.eu/pdfs/human/bwp/026995en.pdf. (Update on Jan 2001)
16. Furuya K, Murai K, Yokoyama T, Maeno H, Takeda Y, Murozuka T, et al. Implementation of a 20-nm pore-size filter in the plasmaderived factor VIII manufacturing process. Vox Sang 2006;91:119-25.
17. Kasper CK and Costa e Silva M. eds. Registry of clotting factor concentrates, 6th ed. Quebec; World federation of hemophilia 2005:1-9.
18. Japanese Red Cross Plasma Fractionation Center. Receipt inspection/virus inactivation and removal. http://www.pfc.jrc.or.jp/01/05.html (Update on Sep 2009)